Amplia Therapeutics: A New Approach to Treating Aggressive Cancers
Melbourne-based medical company Amplia Therapeutics is taking a unique approach in the fight against cancer. Rather than focusing on developing stronger, more toxic chemotherapies, the company is working on a "shield-breaking" treatment that targets the protective walls around hard-to-treat solid tumours, particularly pancreatic cancer. This innovative strategy positions Amplia as a potential partner for some of the world’s largest pharmaceutical companies.
The company has launched a new Phase 2b study in pancreatic cancer, following feedback from the United States Food and Drug Administration (FDA). The trial will test a continuous daily dosing schedule across two potency levels for its FAK protein-inhibiting drug, narmafotinib. The goal is to optimise the therapeutic performance of the drug when used in combination with standard frontline chemotherapy drugs such as gemcitabine and Abraxane.
The trial will initially enrol 12 newly diagnosed patients split into two 6-patient cohorts. Patient enrolment will begin by Q4 2026 across 3 to 4 clinical sites in Australia, with safety, tolerability, and pharmacokinetic assessments slated for completion in Q2 2027.
Understanding the Science Behind Narmafotinib
Narmafotinib is designed to turn off a specific protein called Focal Adhesion Kinase (FAK), which plays a key role in the growth and survival of aggressive tumours. In pancreatic cancer, the tumour often surrounds itself with a dense wall of scar-like tissue, acting as a biological fortress that blocks chemotherapy drugs and even the body’s immune system from penetrating the cancer core.
The FAK protein functions as a stress sensor inside the tumour. When chemotherapy attacks, FAK triggers surrounding cells to pump out even more fibrotic tissue, reinforcing the tumour’s defensive barrier and helping the cancer survive. By breaking down this fibrotic barrier, narmafotinib creates a clearer pathway for standard frontline chemotherapy drugs and the immune system to attack the cancer more effectively.
A Strategic Pivot to Cancer Therapies
Amplia’s journey towards targeted cancer therapies began with a major strategic pivot in 2018. Founded in 2000 as Innate Immunotherapeutics, the company spent two decades developing therapies for multiple sclerosis. However, due to slow progress in the MS field, the company shifted its focus to targeted cancer drugs, which were gaining significant interest from global investors.
In April 2018, the company acquired private developer Amplia Therapeutics, gaining exclusive ownership of a promising group of FAK-inhibitor drugs, including narmafotinib. By September of the same year, shareholders voted to change the name to Amplia Therapeutics, with the ASX ticker ATX.
To lead the company from laboratory testing to human clinical trials, Amplia hired veteran scientist Dr Christopher Burns as CEO and managing director. Chris has over 30 years of pharmaceutical experience, having held top leadership roles at Pfizer and Cytopia. His proven track record of turning laboratory discoveries into approved patient treatments gives Amplia immediate technical credibility.
Clinical Success and Future Prospects
Backed by strong scientific results, Amplia’s ACCENT Trial, a Phase 1b/2a human study combining narmafotinib with frontline pancreatic cancer drugs gemcitabine and abraxane, showed impressive outcomes. The final data from this 64-patient study released in March demonstrated a complete response rate of 7.8%, an objective response rate of 35.9%, and a median overall survival of 11.1 months—showing a 30% improvement over historical chemotherapy-only results.
In parallel with its Phase 2b trials on pancreatic cancer, Amplia has inked a deal with the Australia New Zealand Gynaecological Oncology Group (ANZGOG) to launch a new clinical study evaluating its protein-inhibiting drug on ovarian cancer. This study is actively recruiting 15 to 20 patients to test narmafotinib with standard paclitaxel chemotherapy for advanced, recurrent cases of the devastating disease.
Expanding Opportunities in the KRAS Inhibitor Market
A massive multi-billion-dollar commercial opportunity has emerged from a new global wave of targeted cancer therapies known as KRAS inhibitors. With 64 separate treatments currently in development, the interest in these therapies is enormous because mutations in the KRAS gene are believed to drive more than 90 per cent of all pancreatic cancers.
While other companies are competing in the crowded KRAS field, Amplia is carving out a potentially crucial supporting role for narmafotinib. By combining the drug with KRAS inhibitors, the company believes it can effectively prevent the FAK spike and leave tumours exposed to attack.
Financial Strength and Market Recognition
Amplia is launching into its next clinical trial phase with a healthy A$27.9 million cash balance at the end of March and, with quarterly spending running at about A$3.5 million, the company says it is fully funded to continue advancing through the regulatory pathway. The market appears to have already begun to take notice of Amplia, with its shares surging as much as 185 per cent on a single day following the release of the trial data in March.
Capitalising on this momentum, the company is pushing to uplist its US stock ticker to the prestigious US-based OTCQB Venture Market. This will remove compliance barriers, allowing North American institutional funds, healthcare family offices and everyday American retail investors to buy shares easily.
With the right science, manufacturing, and financial backing, Amplia is well-positioned to make a lasting impact in the field of cancer medicine. Now, it's time for the global registration study to prove if this Melbourne-born player can permanently rewrite the rules of cancer treatment.
No comments:
Post a Comment